Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal ...
FierceBiotech

Napo Pharmaceuticals, Inc. Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals today announces positive clinical data on the effectiveness of crofelemer from a study for CRO-ID in treating severely ill cholera patients ...
FiercePharma

Napo Terminates Glenmark Pharmaceuticals for Failure to Commercially Develop Crofelemer

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. ("Napo") announced today that it has terminated its Collaboration Agreement with Glenmark Pharmaceuticals Ltd. ("Glenmark"), dated July 2, ...
Yahoo Finance

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication ...

"We're very pleased that Napo has been granted a meeting with the FDA to discuss Napo's development plans for crofelemer for MVID - a devastating pediatric disease characterized by severe ...
Nasdaq

Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics S ...
Yahoo Finance

Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs

SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics S ...